Acrivon Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Acrivon Therapeutics, Inc. (ACRV) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.35% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-12
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.98%, a 8.92% decline year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.37%, a 0.92% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.33%, a 1.17% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-09-30 was 4.62%.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.37%, a 4.38% decline from fiscal 2024.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.57%, a 5.58% decline from fiscal 2023.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.84%, a 16.63% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.15%, a 212.03% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.35% 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 3.98% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 4.37% 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 4.37% 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 4.37% 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | 4.37% 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 4.57% 10-K · filed 2026-03-19 | |||
| 2024-09-30 | 4.57% 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | 4.57% 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 4.33% 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 4.84% 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 4.62% 10-Q · filed 2023-11-09 | 4.62% 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | 4.28% 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 4.28% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 4.15% 10-K · filed 2024-03-28 | |||
| 2022-09-30 | 3.16% 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | 1.33% 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |